Continuing to follow through on its previously announced strategic focus on five key business areas, Takeda Pharmaceutical Company (NYSE:TAK) has agreed to sell a lineup of non-core prescription medicines marketed predominantly in Europe and Canada to German drug firm Cheplapharm for ~$562M.
The portfolio, which generated ~$260M in net sales in fiscal 2019, includes cardiovascular/metabolic and anti-inflammatory products along with Calcium.
The transaction should close by the end of Q1 2021.
https://seekingalpha.com/news/3611980-takeda-divests-certain-non-core-assets-to-cheplapharm-for-562m
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.